Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 31Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Breast Neoplasms 19Lymphoma 18Multiple Myeloma 17Glioblastoma 17Prostatic Neoplasms 16Urinary Bladder Neoplasms 15Glioma 15Carcinoma, Renal Cell 15Melanoma 13Squamous Cell Carcinoma of Head and Neck 12Sarcoma 12Ovarian Neoplasms 12Colorectal Neoplasms 12Central Nervous System Neoplasms 12Triple Negative Breast Neoplasms 11Mouth Neoplasms 11Pancreatic Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Laryngeal Neoplasms 10Carcinoma, Transitional Cell 10Thyroid Neoplasms 9Fallopian Tube Neoplasms 9Ependymoma 9

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Muscle Invasive Bladder Urothelial Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡